JAK/STAT Signaling
Various ligands including cytokines (e.g. interferons and interleukins), hormones (e.g. erythropoietin and growth hormone) and their cell surface receptors activate JAK proteins, which autophosphorylate, and then phosphorylate the receptor. Subsequently, JAKs phosphorylate a specific tyrosine residue on the STAT protein, promoting dimerization via SH2 domains. The activated STATs form homo-/heterodimers and translocate to the nucleus to trigger target gene transcription. In addition, suppressors of cytokine signaling (SOCS) family inhibit receptor signaling via homologous or heterologous feedback regulation. Dysregulation in JAK/STAT signaling is associated with diseases such as atherosclerosis, immunodeficiencies and cancer.
- A3967 Lapatinib DitosylateTarget: EGFR|ErbB-2Summary: EGFR/HER2 inhibitor,potent and selective
- A8218 Lapatinib2 CitationTarget: ErbBSummary: EGFR/HER2 inhibitor,potent,selective and reversible
- A8219 Gefitinib (ZD1839)3 CitationTarget: EGFRSummary: Selective EGFR inhibitor
- A8247 Afatinib (BIBW2992)1 CitationTarget: EGFRSummary: Irreversible EGFR/HER2 inhibitor
- A2412 CP-724714Target: VEGFR|PDGFR|Bcr-Abl|Src|EGFR|c-MET|Insulin Receptors|IRG-1RSummary: HER2 inhibitor,potent and selective
- A2822 AC480 (BMS-599626)Target: EGFRSummary: HER1/2 inhibitor,selective and efficacious
- A2024 PD168393Target: PDGFR|FGFR|EGFR|PKC|insulinSummary: EGFR inhibitor
- A2689 ButeinTarget: Src|STAT|EGFR|Angiotensin-Converting Enzymes (ACEs)|5-Lipoxygenases|PTK|enoyl-acyl-carrier protein reductaseSummary: Protein kinase inhibitor
- A8319 Dacomitinib (PF299804, PF299)Target: ErbBSummary: HER inhibitor
- A8322 Neratinib (HKI-272)1 CitationTarget: EGFRSummary: HER2/EGFR inhibitor,potent and irreversible